Treating COVID-19 Based on Disease Severity: Key Considerations in Hospitalized Patients

Treating COVID-19 Based on Disease Severity: Key Considerations in Hospitalized Patients

 

View Activity

FACULTY

William A. Fischer II, MD
Associate Professor of Medicine, Pulmonary and Critical Care Medicine
Director of Emerging Pathogens
Institute for Global Health and Infectious Diseases
The University of North Carolina
Chapel Hill, NC

PROGRAM OVERVIEW

In this educational activity, expert faculty will discuss the use of approved and authorized treatments for the management of patients hospitalized with COVID-19. A review of clinical trial data on the efficacy and safety of therapeutic options and strategies for selecting therapy based on disease severity and clinical factors will allow clinicians to reduce the need for invasive ventilation and improve patient outcomes.

TARGET AUDIENCE

This activity is designed to meet the educational needs of and provide tools for the entire healthcare community. Participants can range from a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, primary care, advanced practitioners, nurses, paramedics, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Evaluate clinical trial of therapies with EUAs for treating patients with COVID-19
• Choose appropriate treatment across the spectrum of disease severity in hospitalized patients with COVID-19
• Explain the impact of SARS-CoV-2 variants on the efficacy and safety of EUA therapies for the treatment of COVID-19 in improving clinical outcomes among hospitalized patients
• Recognize best practices for use of immunosuppressive therapies to reduce the need for invasive ventilation in patients admitted to intensive care units
• Use tools and resources developed to promote the delivery of therapies to people with COVID-19 including underserved populations

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with COVID-19.
CNE Credits: 0.5 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 0.5 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Fischer discloses that he has been contracted for COVID-19 research for Ridgeback Biopharmaceuticals and has worked as a consultant for Merck and Roche. He also worked for Syneos Health and Janssen for adjudication of adverse events in respiratory syncytial virus (RSV) and influenza studies, respectively, and served as the site principal investigator for the Phase 1 Lilly study of bamlanivimab and for the Phase 2 study of casirivimab/imdevimab at the University of North Carolina.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.
Staff Planners and Managers

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

• • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
  • Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.
  • Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

• • 1. Read the CME/CNE information and faculty disclosures.
    2. Participate in the enduring activity.
    3. Submit the evaluation form to Med Learning Group.

You will receive your certificate as a downloadable file upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making experience before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: May 31, 2022

EXPIRATION DATE: May 31, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.